

FORM PTO-1449/A and B (Modified)			APPLICATION NO.: 09/464,303	ATTY. DOCKET NO.: A0752.70001US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: December 15, 1999	CONFIRMATION NO.: 7348
			APPLICANT: Stahl et al.	
			GROUP ART UNIT: 1644	EXAMINER: Francois P. Vandervegt
Sheet	1	of		



### U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

### FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
R	B10	WO	90/08549	A1	Speck, Ulrich	08-09-1990	Abstract only
	B11	WO	93/18775	A1	The University of British Columbia	09-30-1993	
	B12	WO	97/31121	A1	The University of British Columbia	08-28-1997	

### OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
R	C39	AGAH et al., Isolation, cloning and functional characterization of porcine mannose-binding lectin. <i>Immunology</i> . 2001 Mar;102(3):338-43.	
	C40	BHOLE et al., Therapeutic potential of targeting the complement cascade in critical care medicine. <i>Crit Care Med</i> . 2003 Jan;31(1 Suppl):S97-104. Review.	
	C41	BLUME et al., Activated endothelial cells elicit paracrine induction of epithelial chloride secretion. 6-Keto-PGF1alpha is an epithelial secretagogue. <i>J Clin Invest</i> . 1998 Sep 15;102(6):1161-72.	
	C42	COLLARD et al., Complement activation following reoxygenation of hypoxic human endothelial cells: role of intracellular reactive oxygen species, NF-kappaB and new protein synthesis. <i>Immunopharmacology</i> . 1998 Mar;39(1):39-50.	
	C43	COLLARD et al., Complement activation following oxidative stress. <i>Mol Immunol</i> . 1999 Sep-Oct;36(13-14):941-8. Review.	
	C44	COLLARD et al., Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. <i>Am J Pathol</i> . 2001 Sep;159(3):1045-54.	
	C45	COLLARD et al., Complement activation after oxidative stress: role of the lectin complement pathway. <i>Am J Pathol</i> . 2000 May;156(5):1549-56.	
	C46	COLLARD et al., Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway. <i>Circulation</i> . 1997 Jul 1;96(1):326-33.	
	C47	DAHL et al., MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. <i>Immunity</i> . 2001 Jul;15(1):127-35.	
	C48	FIANE et al., Mechanism of complement activation and its role in the inflammatory response after thoracoabdominal aortic aneurysm repair. <i>Circulation</i> . 2003 Aug 19;108(7):849-56. Epub 2003 Aug 04.	
	C49	HART et al., Initiation of complement activation following oxidative stress. In vitro and in vivo observations. <i>Mol Immunol</i> . 2004 Jun;41(2-3):165-71. Review.	
	C50	HOLT et al., Domain antibodies: proteins for therapy. <i>Trends Biotechnol</i> . 2003 Nov;21(11):484-90. Review.	
	C51	IGARASHI et al., Specific binding of a synthetic peptide derived from an antibody complementarity determining region to phosphatidylserine. <i>J Biochem (Tokyo)</i> . 1995 Feb;117(2):452-7.	
	C52	JORDAN et al., Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. <i>Circulation</i> . 2001 Sep 18;104(12):1413-8.	
	C53	KINGMAN, Complement activation in myocardial infarction: A target for future treatments? <i>Drug Discovery Today</i> . 2000; 8: 313-4.	
	C54	LANZREIN et al., Mannan-binding lectin in human serum, cerebrospinal fluid and brain tissue and its role in Alzheimer's disease. <i>Neuroreport</i> . 1998 May 11;9(7):1491-5.	

811314.1

*O.D.P. [Signature]* 2/15/05

FORM PTO-1449/A and B (Modified)			APPLICATION NO.: 09/464,303	ATTY. DOCKET NO.: A0752.70001US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: December 15, 1999	CONFIRMATION NO.: 7348
			APPLICANT: Stahl et al.	
Sheet	2	of	2	GROUP ART UNIT: 1644
			EXAMINER: Francois P. Vandervegt	

<i>PR</i>	C55	LAUNE et al., Systematic exploration of the antigen binding activity of synthetic peptides isolated from the variable regions of immunoglobulins. <i>J Biol Chem.</i> 1997 Dec 5;272(49):30937-44.		
	C56	LEKOWSKI et al., Ulex europeus agglutinin II (UEA-II) is a novel, potent inhibitor of complement activation. <i>Protein Sci.</i> 2001 Feb;10(2):277-84.		
	C57	MONNET et al., Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells. <i>J Biol Chem.</i> 1999 Feb 5;274(6):3789-96.		
	C58	MONTALTO et al., A keratin peptide inhibits mannose-binding lectin. <i>J Immunol.</i> 2001 Mar 15;166(6):4148-53.		
	C59	MONTALTO et al., Role for complement in mediating intestinal nitric oxide synthase-2 and superoxide dismutase expression. <i>Am J Physiol Gastrointest Liver Physiol.</i> 2003 Jul;285(1):G197-206. Epub 2003 Mar 13.		
	C60	RIEBEN et al., Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. <i>Blood.</i> 1999 Feb 1;93(3):942-51.		
	C61	ROOS et al., Human IgA activates the complement system via the mannose-binding lectin pathway. <i>J Immunol.</i> 2001 Sep 1;167(5):2861-8.		
	C62	ROOS et al., Therapeutic inhibition of the early phase of complement activation. <i>Immunobiology.</i> 2002 Sep;205(4-5):595-609. Review.		
	C63	ROOS et al., Functional characterization of the lectin pathway of complement in human serum. <i>Mol Immunol.</i> 2003 Jan;39(11):655-68.		
	C64	RUSSELL et al., Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: inhibition of IgG-mediated complement activation. <i>Eur J Immunol.</i> 1989 Dec;19(12):2243-9.		
	C65	STAHL, The Immune System - Complementary Medicine. <i>The Economist.</i> 2000 May 13; 26-7.		
	C66	STAHL, New Inflammatory Pathway Discovered. <i>Genetic Engineering News.</i> 2000 May 15; 20(3):27-8.		
	C67	STAHL et al., Reperfusion injury in surgery. Role of the endothelium, oxidative stress and complement activation (Invited review). <i>New Surgery.</i> 2001; 1:62-6.		
	C68	STAHL et al., Role for the alternative complement pathway in ischemia/reperfusion injury. <i>Am J Pathol.</i> 2003 Feb;162(2):449-55.		
	C69	SZEBENI et al., Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. <i>Am J Physiol Heart Circ Physiol.</i> 2000 Sep;279(3):H1319-28.		
	C70	SZEBENI et al., Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. <i>Circulation.</i> 1999 May 4;99(17):2302-9.		
	C71	TAUB et al., A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen. <i>J Biol Chem.</i> 1989 Jan 5;264(1):259-65.		
	C72	TOFUKUJI et al., Anti-C5a monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction. <i>J Thorac Cardiovasc Surg.</i> 1998 Dec;116(6):1060-8.		
	C73	WALLIS et al., Localization of the serine protease-binding sites in the collagen-like domain of mannose-binding protein: indirect effects of naturally occurring mutations on protease binding and activation. <i>J Biol Chem.</i> 2004 Apr 2;279(14):14065-73. Epub 2004 Jan 14.		
	C74	WALSH et al., Role of complement in myocardial ischemia and infarction. In: Szebeni J, editor. <i>The Complement System. Novel Roles in Health and Disease.</i> Kluwer Academic Publishers. Massachusetts, June 2004.		
	C75	WALSH et al., Myocardial Ischemia-reperfusion injury is dependent on lectin complement activation. <i>American College of Cardiology.</i> 2004 Mar 10; 11:15am-11:30am (Presentation Abstract).		
	C76	ZHAO et al., Anoxia and reoxygenation of human endothelial cells decrease ceramide glucosyltransferase expression and activates caspases. <i>FASEB J.</i> 2003 Apr;17(6):723-4. Epub 2003 Feb 05.		
	C77	ZHAO et al., Identification of human mannose binding lectin (MBL) recognition sites for novel inhibitory antibodies. <i>Hybridoma and Hybridomics.</i> 2002 Feb;21(1):25-36.		
	C78	ZHAO et al., Murine model of gastrointestinal ischemia associated with complement-dependent injury. <i>J Appl Physiol.</i> 2002 Jul;93(1):338-45.		

EXAMINER	<i>F. P. Vandervegt</i>	DATE CONSIDERED	2/15/05
----------	-------------------------	-----------------	---------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449/A and B (Modified) <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 09/464,303	ATTY. DOCKET NO.: A0752.70001US00
				FILING DATE: December 15, 1999	CONFIRMATION NO.: 7348
				APPLICANT: Stahl et al.	
Sheet	1	of	1	GROUP ART UNIT: 1644	EXAMINER: Francois P. Vandervegt

#### U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
R	A2	5,616,311		Yen et al.	04-01-1997

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

#### OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
R	C79	LEKOWSKI et al., Ulex europaeus Agglutinin II (UEA-II) is a novel, potent inhibitor of complement activation on human endothelial cells. 72nd Scientific Sessions of the American Heart Association. Atlanta, Georgia, USA. November 7-10, 1999. Circulation. 1999 Nov 2;100(18 Suppl):I.259. Abstract.	
	C80	MATSUSHITA et al., Human mannose-binding protein is identical to a component of Ra-reactive factor. Biochem Biophys Res Commun. 1992 Mar 16;183(2):645-51.	
	C81	SUMMERFIELD et al., Mannose-binding proteins in human serum: identification of mannose-specific immunoglobulins and a calcium-dependent lectin, of broader carbohydrate specificity, secreted by hepatocytes. Biochim Biophys Acta. 1986 Sep 4;883(2):197-206.	

EXAMINER:

DATE CONSIDERED:

2/15/04 05<sup>th</sup>

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.49(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]